Immuneering to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Rhea-AI Summary

Immuneering Corporation (Nasdaq: IMRX) announced it will release its fourth-quarter and full-year financial results for 2022 on March 6, 2023, after market close. Following the announcement, management will host a conference call at 4:30 p.m. ET to discuss the results. The company is focused on developing a universal-RAS therapy aimed at treating cancer patients, with its lead product candidate, IMM-1-104, currently in Phase 1/2a studies. Immuneering also has a significant pipeline, including the accelerated development program IMM-6-415 for RAS mutation patients.

Positive

• Focus on developing a universal-RAS therapy potentially benefiting a wide range of cancer patients.
• Lead product candidate, IMM-1-104, in Phase 1/2a study with promising therapeutic implications.
• Additional pipeline program, IMM-6-415, indicates an expanding research focus.

Negative

• None.

Management to host conference call on Monday, March 6 at 4:30 p.m. ET  

CAMBRIDGE, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy, today announced that it plans to release financial results for the fourth quarter and full year ended December 31, 2022 on Monday, March 6 after the close of trading. Immuneering’s management team will host a conference call and webcast beginning at 4:30 p.m. ET.

To access the call by phone, please use this registration link, and you will be provided with dial in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. After the live webcast, the event will be archived for 90 days in the Investor Relations section of Immuneering’s website at Events & Presentations.

About Immuneering Corporation

Immuneering is a clinical-stage oncology company developing medicines for broad populations of cancer patients with an initial aim to develop a universal-RAS therapy. The company aims to achieve universal activity through deep cyclic inhibition of the MAPK pathway, impacting cancer cells while sparing healthy cells. Immuneering’s lead product candidate, IMM-1-104, is in a Phase 1/2a study in patients with advanced solid tumors harboring RAS mutations. The company’s development pipeline also includes IMM-6-415, which is designed to have an accelerated cadence relative to IMM-1-104, as well as several early-stage programs. For more information, please visit www.immuneering.com

Media Contact:
Gina Nugent
Nugent Communications
617-460-3579
gina@nugentcommunications.com

Investor Contact:
Laurence Watts
Gilmartin Group
619-916-7620
laurence@gilmartinir.com

FAQ

When will Immuneering release its financial results for 2022?

Immuneering will release its financial results on March 6, 2023, after market close.

What is the lead product candidate of Immuneering?

The lead product candidate is IMM-1-104, currently in Phase 1/2a studies.

What time is the Immuneering conference call?

The conference call will take place at 4:30 p.m. ET on March 6, 2023.

What is the focus of Immuneering Corporation?

Immuneering is focused on developing medicines for cancer patients, particularly a universal-RAS therapy.